John R Burnett

List of Publications by Year
in descending order

129 papers	4,602 citations	101543 36 h-index	114465 63 g-index
131 all docs	131 docs citations	131 times ranked	5082 citing authors

#	Article	IF	Citations
1	Pilot study of universal screening of children and childâ€parent cascade testing for familial hypercholesterolaemia in Australia. Journal of Paediatrics and Child Health, 2022, 58, 281-287.	0.8	11
2	Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a). Atherosclerosis, 2022, 349, 219-226.	0.8	11
3	Incidental diagnosis of LPL deficiency in an infant presenting with an acute respiratory infection. Clinica Chimica Acta, 2022, 529, 1-3.	1.1	0
4	Lipoprotein apheresis and <scp>PCSK9</scp> inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand. Journal of Clinical Apheresis, 2021, 36, 48-58.	1.3	5
5	Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. Heart Lung and Circulation, 2021, 30, 324-349.	0.4	51
6	The lipid profile in children prior to isotretinoin therapy: an opportunity to detect familial hypercholesterolaemia. Pathology, 2021, 53, 288-290.	0.6	0
7	Homozygous autosomal recessive hypercholesterolaemia in a South Asian child presenting with multiple cutaneous xanthomata. Annals of Clinical Biochemistry, 2021, 58, 153-156.	1.6	1
8	Gaps in the Care of Familial Hypercholesterolaemia in Australia: First Report From the National Registry. Heart Lung and Circulation, 2021, 30, 372-379.	0.4	14
9	Publication metrics: it really is all about the numbers. Pathology, 2021, 53, 561-563.	0.6	2
10	l-asparaginase-induced biochemical toxicities in young adults with acute lymphoblastic leukaemia and T-lymphoblastic lymphoma. Pathology, 2021, 53, 924-926.	0.6	1
11	A genetic risk score predicts coronary artery disease in familial hypercholesterolaemia: enhancing the precision of risk assessment. Clinical Genetics, 2020, 97, 257-263.	2.0	7
12	Coronary artery disease and the risk-associated LPA variants, rs3798220 and rs10455872, in patients with suspected familial hypercholesterolaemia. Clinica Chimica Acta, 2020, 510, 211-215.	1.1	11
13	Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk. Journal of the American College of Cardiology, 2020, 76, 2736-2739.	2.8	39
14	Publication metrics: what do they mean?. Pathology, 2020, 52, 619-620.	0.6	5
15	Tangier disease: update for 2020. Current Opinion in Lipidology, 2020, 31, 80-84.	2.7	29
16	An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia. Atherosclerosis, 2020, 298, 52-57.	0.8	14
17	Design, development and deployment of a web-based patient registry for rare genetic lipid disorders. Pathology, 2020, 52, 447-452.	0.6	3
18	Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic?. Clinical Chemistry, 2019, 65, 1258-1266.	3.2	37

#	Article	IF	Citations
19	Update on the diagnosis, treatment and management of rare genetic lipid disorders. Pathology, 2019, 51, 193-201.	0.6	14
20	Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology, 2019, 51, 148-154.	0.6	113
21	Lipids and cardiovascular disease. Pathology, 2019, 51, 129-130.	0.6	5
22	Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis. Clinical Cardiology, 2018, 41, 378-384.	1.8	36
23	Parentâ€“child genetic testing for familial hypercholesterolaemia in an Australian context. Journal of Paediatrics and Child Health, 2018, 54, 741-747.	0.8	18
24	A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1704-1714.	3.6	41
25	The role of patient registries for rare genetic lipid disorders. Current Opinion in Lipidology, 2018, 29, 156-162.	2.7	20
26	PCSK9 â€" A Journey to Cardiovascular Outcomes. New England Journal of Medicine, 2018, 379, 2161-2162.	27.0	18
27	The Present and the Future of Genetic Testing in Familial Hypercholesterolemia: Opportunities and Caveats. Current Atherosclerosis Reports, 2018, 20, 31.	4.8	19
28	Documenting family history in children with hypercholesterolaemia: A lost opportunity. Journal of Paediatrics and Child Health, 2017, 53, 470-473.	0.8	5
29	Clinical utility gene card for: Sitosterolaemia. European Journal of Human Genetics, 2017, 25, 512-512.	2.8	14
30	Clinical utility gene card for: Tangier disease. European Journal of Human Genetics, 2017, 25, e1-e3.	2.8	7
31	Lipoprotein Lipase Deficiency in an Infant With Chylomicronemia, Hepatomegaly, and Lipemia Retinalis. Global Pediatric Health, 2017, 4, 2333794X1771583.	0.7	0
32	Filiarial chyluria with nephrotic-range proteinuria and associated hypoalbuminaemia and hypogammaglobulinaemia secondary to bilateral lymphorenal fistulae. BMJ Case Reports, 2017, 2017, bcr-2017-221114.	0.5	1
33	Isolated brachydactyly type E and idiopathic pancreatitis in a patient presenting to a lipid disorders clinic. BMJ Case Reports, 2017, 2017, bcr-2016-218825.	0.5	1
34	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. Nature Reviews Endocrinology, 2016, 12, 467-484.	9.6	28
35	Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions. Journal of Clinical Lipidology, 2016, 10, 1329-1337.e3.	1.5	46
36	Interpretative comments specifically suggesting specialist referral increase the detection of familial hypercholesterolaemia. Pathology, 2016, 48, 463-466.	0.6	13

#	Article	IF	Citations
37	Ï‰-3 Fatty Acid Ethyl Esters Diminish Postprandial Lipemia in Familial Hypercholesterolemia. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3732-3739.	3.6	29
38	High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency. Atherosclerosis, 2016, 253, 7-14.	0.8	23
39	Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?. Expert Opinion on Pharmacotherapy, 2016, 17, 275-281.	1.8	9
40	Novel APOB missense variants, A224T and V925L, in a black South African woman with marked hypocholesterolemia. Journal of Clinical Lipidology, 2016, 10, 604-609.	1.5	2
41	Lipoprotein metabolism in an apoB-80 familial hypobetalipoproteinemia heterozygote. Clinical Biochemistry, 2016, 49, 720-722.	1.9	2
42	Lipoprotein lipase deficiency presenting with neonatal perianal abscesses. BMJ Case Reports, 2016, 2016, bcr2015212587.	0.5	5
43	Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1484-E1490.	3.6	6
44	Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience. Atherosclerosis, 2015, 239, 93-100.	0.8	65
45	HDL Particle Size Is a Critical Determinant of ABCA1-Mediated Macrophage Cellular Cholesterol Export. Circulation Research, 2015, 116, 1133-1142.	4.5	240
46	Clinical utility gene card for: Familial hypobetalipoproteinaemia (APOB) â€“ Update 2014. European Journal of Human Genetics, 2015, 23, 889-889.	2.8	10
47	SPG11 mutation in a Turkish familial hypobetalipoproteinemia family with hereditary spastic paraplegia. Clinica Chimica Acta, 2015, 445, 1.	1.1	0
48	Contemporary Aspects of the Biology and Therapeutic Regulation of the Microsomal Triglyceride Transfer Protein. Circulation Research, 2015, 116, 193-205.	4.5	58
49	Clinical utility gene card for: Abetalipoproteinaemia â€“ Update 2014. European Journal of Human Genetics, 2015, 23, 889-889.	2.8	8
50	Vitamin E and oxidative stress in abetalipoproteinemia and familial hypobetalipoproteinemia. Free Radical Biology and Medicine, 2015, 88, 59-62.	2.9	129
51	Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. International Journal of Cardiology, 2015, 201, 633-638.	1.7	66
52	The potential role of an expert computer system to augment the opportunistic detection of individuals with familial hypercholesterolaemia from a community laboratory. Clinica Chimica Acta, 2015, 448, 18-21.	1.1	13
53	Finding the Therapeutic Sweet Spot. Circulation: Cardiovascular Genetics, 2015, 8, 637-639.	5.1	4
54	Genetic Abetalipoproteinaemia and Hypobetalipoproteinaemia. Contemporary Endocrinology, 2015, , 251-266.	0.1	0

#	Article	IF	Citations
55	Clinical features and genetic analysis of three patients with severe hypertriglyceridaemia. Annals of Clinical Biochemistry, 2014, 51, 485-489.	1.6	13
56	A novel missense SMPD1 gene mutation, T460P, and clinical findings in a patient with Niemannâ€“Pick disease type B presenting to a lipid disorders clinic. Annals of Clinical Biochemistry, 2014, 51, 615-618.	1.6	3
57	Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects. Journal of the American College of Cardiology, 2014, 63, 2365-2373.	2.8	57
58	Detecting familial hypercholesterolaemia in the community: Impact of a telephone call from a chemical pathologist to the requesting general practitioner. Atherosclerosis, 2014, 234, 469-472.	0.8	27
59	Update on Primary Hypobetalipoproteinemia. Current Atherosclerosis Reports, 2014, 16, 423.	4.8	48
60	Novel missense MTTP gene mutations causing abetalipoproteinemia. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 1548-1554.	2.4	24
61	Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 387-403.	4.7	30
62	Running interference to lower cholesterol. Lancet, The, 2014, 383, 10-12.	13.7	7
63	Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Expert Opinion on Biological Therapy, 2013, 13, 429-435.	3.1	45
64	Non-alcoholic steatohepatitis-related cirrhosis in a patient with APOB L343V familial hypobetalipoproteinaemia. Clinica Chimica Acta, 2013, 421, 121-125.	1.1	11
65	Recent developments in the genetics of LDL deficiency. Current Opinion in Lipidology, 2013, 24, 111-115.	2.7	12
66	Protein Kinase C Controls Vesicular Transport and Secretion of Apolipoprotein E from Primary Human Macrophages. Journal of Biological Chemistry, 2013, 288, 5186-5197.	3.4	19
67	Opportunistic screening for familial hypercholesterolaemia via a community laboratory. Annals of Clinical Biochemistry, 2012, 49, 534-537.	1.6	51
68	Clinical utility gene card for: Abetalipoproteinaemia. European Journal of Human Genetics, 2012, 20, 1-3.	2.8	37
69	Dalcetrapib, a cholesteryl ester transfer protein modulator. Expert Opinion on Investigational Drugs, 2012, 21, 1427-1432.	4.1	17
70	Screening for familial hypercholesterolaemia. Pathology, 2012, 44, 122-128.	0.6	27
71	Genetic analysis of familial hypercholesterolaemia in Western Australia. Atherosclerosis, 2012, 224, 430-434.	0.8	61
72	Clinical utility gene card for: Familial Hypobetalipoproteinaemia (APOB). European Journal of Human Genetics, 2012, 20, 3-3.	2.8	14

#	Article	IF	Citations
73	Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Vascular Health and Risk Management, 2012, 8, 651.	2.3	43
74	Anacetrapib, a cholesteryl ester transfer protein inhibitor. Expert Opinion on Investigational Drugs, 2012, 21, 103-109.	4.1	9
75	Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opinion on Investigational Drugs, 2011, 20, 265-272.	4.1	60
76	Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. Critical Reviews in Clinical Laboratory Sciences, 2011, 48, 1-18.	6.1	57
77	Familial hypercholesterolaemia: A model of care for Australasia. Atherosclerosis Supplements, 2011, 12, 221-263.	1.2	181
78	Genetic determinants of hepatic steatosis in man. Journal of Lipid Research, 2011, 52, 593-617.	4.2	115
79	Hypobetalipoproteinaemia secondary to chronic hepatitis C virus infection in a patient with familial hypercholesterolaemia. Annals of Clinical Biochemistry, 2009, 46, 420-422.	1.6	8
80	A novel missense HGD gene mutation, K57N, in a patient with alkaptonuria. Clinica Chimica Acta, 2009, 403, 254-256.	1.1	11
81	A novel ABCA1 nonsense mutation, R1270X, in Tangier disease associated with an unrecognised bleeding tendency. Clinica Chimica Acta, 2009, 409, 136-139.	1.1	13
82	Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency. Current Opinion in Molecular Therapeutics, 2009, 11, 681-91.	2.8	29
83	Vitamin E in Human Health and Disease. Critical Reviews in Clinical Laboratory Sciences, 2008, 45, 417-450.	6.1	156
84	Familial hypobetalipoproteinemia in a Turkish family with hereditary spastic paraplegia. Clinica Chimica Acta, 2008, 390, 152-155.	1.1	5
85	High-resolution melting analysis for detection of familial ligand-defective apolipoprotein B-100 mutations. Annals of Clinical Biochemistry, 2008, 45, 170-176.	1.6	22
86	Estimating LDL ApoB: Infomania or Clinical Advance?. Clinical Chemistry, 2008, 54, 782-784.	3.2	2
87	Common and rare gene variants affecting plasma LDL cholesterol. Clinical Biochemist Reviews, 2008, 29, 11-26.	3.3	45
88	Phenylketonuria: an inborn error of phenylalanine metabolism. Clinical Biochemist Reviews, 2008, 29, 31-41.	3.3	255
89	Missense Mutations in APOB within the Î²Î±1 Domain of Human APOB-100 Result in Impaired Secretion of ApoB and ApoB-containing Lipoproteins in Familial Hypobetalipoproteinemia. Journal of Biological Chemistry, 2007, 282, 24270-24283.	3.4	66
90	Postprandial Lipoprotein Metabolism in Familial Hypobetalipoproteinemia. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1474-1478.	3.6	29

#	Article	IF	Citations
91	The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis, 2007, 193, 445-448.	0.8	323
92	MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?. Expert Opinion on Therapeutic Targets, 2007, 11, 181-189.	3.4	54
93	Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria. IDrugs: the Investigational Drugs Journal, 2007, 10, 805-13.	0.7	14
94	New therapies for familial hypercholesterolemia. Expert Opinion on Therapeutic Patents, 2006, 16, 349-361.	5.0	0
95	Assessment of Tocopherol Metabolism and Oxidative Stress in Familial Hypobetalipoproteinemia. Clinical Chemistry, 2006, 52, 1339-1345.	3.2	31
96	Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. Expert Opinion on Investigational Drugs, 2006, 15, 1337-1351.	4.1	25
97	Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia. IDrugs: the Investigational Drugs Journal, 2006, 9, 495-9.	0.7	0
98	Drug evaluation: TAK-475--an oral inhibitor of squalene synthase for hyperlipidemia. Current Opinion in Investigational Drugs, 2006, 7, 850-6.	2.3	8
99	Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia. Current Opinion in Molecular Therapeutics, 2006, 8, 461-7.	2.8	12
100	Familial hypercholesterolaemia: a look back, a look ahead. Medical Journal of Australia, 2005, 183, 222-223.	1.7	0
101	Familial hypercholesterolaemia: a look back, a look ahead. Medical Journal of Australia, 2005, 182, 552-553.	1.7	19
102	Liver Dysfunction and Steatosis in Familial Hypobetalipoproteinemia. Clinical Chemistry, 2005, 51, 266-269.	3.2	35
103	The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1738, 10-18.	2.4	8
104	Monogenic Hypocholesterolaemic Lipid Disorders and Apolipoprotein B Metabolism. Critical Reviews in Clinical Laboratory Sciences, 2005, 42, 515-545.	6.1	90
105	Familial hypercholesterolaemia: a look back, a look ahead. Medical Journal of Australia, 2005, 182, 552-3.	1.7	7
106	Torcetrapib + atorvastatin (Pfizer). Current Opinion in Investigational Drugs, 2005, 6, 944-50.	2.3	1
107	â€œMilkyâ€•urine: a case of chyluria. Medical Journal of Australia, 2004, 180, 89-89.	1.7	7
108	Lipid Disorders and Mutations in the APOB Gene. Clinical Chemistry, 2004, 50, 1725-1732.	3.2	191

#	Article	IF	Citations
109	Lipids, lipoproteins, atherosclerosis and cardiovascular disease. Clinical Biochemist Reviews, 2004, 25, 2.	3.3	63
110	A Novel Nontruncating APOB Gene Mutation, R463W, Causes Familial Hypobetalipoproteinemia. Journal of Biological Chemistry, 2003, 278, 13442-13452.	3.4	82
111	Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB. Journal of Lipid Research, 2003, 44, 943-952.	4.2	27
112	Eflucimibe. Pierre Fabre/Eli Lilly. Current Opinion in Investigational Drugs, 2003, 4, 347-51.	2.3	7
113	FM-VP4 Forbes Medi-Tech. Current Opinion in Investigational Drugs, 2003, 4, 1120-5.	2.3	4
114	Inhibition of the Apical Sodium-Dependent Bile Acid Transporter Reduces LDL Cholesterol and ApoB by Enhanced Plasma Clearance of LDL ApoB. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1884-1891.	2.4	58
115	Apolipoprotein B Metabolism: Tracer Kinetics, Models, and Metabolic Studies. Critical Reviews in Clinical Laboratory Sciences, 2002, 39, 89-137.	6.1	37
116	Cardiovascular disease and osteoporosis: is there a link between lipids and bone?. Annals of Clinical Biochemistry, 2002, 39, 203-210.	1.6	50
117	Avasimibe Pfizer. Current Opinion in Investigational Drugs, 2002, 3, 1328-33.	2.3	3
118	Measuring myocardial damage. Medical Journal of Australia, 2001, 174, 163-164.	1.7	1
119	Therapeutic considerations for postprandial dyslipidaemia. Diabetes, Obesity and Metabolism, 2001, 3, 143-156.	4.4	7
120	Câ€reactive protein: a new cardiovascular risk factor?. Medical Journal of Australia, 2000, 173, 117-118.	1.7	4
121	Common and Rare ABCA1 Variants Affecting Plasma HDL Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1983-1989.	2.4	117
122	The Magnitude of Decrease in Hepatic Very Low Density Lipoprotein Apolipoprotein B Secretion Is Determined by the Extent of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition in Miniature Pigs1. Endocrinology, 1999, 140, 5293-5302.	2.8	48
123	Acyl coenzyme A: cholesterol acyltransferase inhibition and hepatic apolipoprotein B secretion. Clinica Chimica Acta, 1999, 286, 231-242.	1.1	33
124	Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Journal of Lipid Research, 1999, 40, 1317-1327.	4.2	70
125	Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: effect of dietary fat and cholesterol. Lipids and Lipid Metabolism, 1998, 1393, 63-79.	2.6	21
126	The HMG-CoA Reductase Inhibitor Atorvastatin Increases the Fractional Clearance Rate of Postprandial Triglyceride-Rich Lipoproteins in Miniature Pigs. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1906-1914.	2.4	33

#	Article	IF	Citations
127	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Current Opinion in Lipidology, 1997, 8, 138-145.	2.7	95
128	Inhibition of HMG-CoA Reductase by Atorvastatin Decreases Both VLDL and LDL Apolipoprotein B Production in Miniature Pigs. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2589-2600.	2.4	90
129	Familial hypobetalipoproteinaemia: a rare presentation to the lipid clinic. Medical Journal of Australia, 1993, 159, 272-274.	1.7	8